Victory Capital Management Inc. Cuts Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Victory Capital Management Inc. decreased its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBHGet Rating) by 1.7% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 184,136 shares of the medical equipment provider’s stock after selling 3,145 shares during the quarter. Victory Capital Management Inc. owned about 0.09% of Zimmer Biomet worth $19,251,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Virtu Financial LLC purchased a new position in Zimmer Biomet in the second quarter worth $882,000. Assetmark Inc. raised its position in Zimmer Biomet by 52.4% in the third quarter. Assetmark Inc. now owns 22,174 shares of the medical equipment provider’s stock worth $2,318,000 after acquiring an additional 7,621 shares in the last quarter. Bradley Foster & Sargent Inc. CT raised its position in Zimmer Biomet by 18.6% in the second quarter. Bradley Foster & Sargent Inc. CT now owns 6,367 shares of the medical equipment provider’s stock worth $669,000 after acquiring an additional 1,000 shares in the last quarter. Ballentine Partners LLC raised its position in Zimmer Biomet by 5.5% in the third quarter. Ballentine Partners LLC now owns 4,130 shares of the medical equipment provider’s stock worth $432,000 after acquiring an additional 217 shares in the last quarter. Finally, Czech National Bank purchased a new position in Zimmer Biomet in the third quarter worth $2,549,000. Hedge funds and other institutional investors own 87.21% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on ZBH shares. StockNews.com started coverage on Zimmer Biomet in a research report on Wednesday, October 12th. They issued a “buy” rating for the company. Jefferies Financial Group started coverage on Zimmer Biomet in a research report on Wednesday, October 12th. They issued an “underperform” rating and a $95.00 price target for the company. Citigroup raised their price target on Zimmer Biomet from $116.00 to $130.00 and gave the company a “neutral” rating in a research report on Monday, December 12th. Piper Sandler raised their price target on Zimmer Biomet from $120.00 to $130.00 in a research report on Thursday, January 5th. Finally, Morgan Stanley raised their price target on Zimmer Biomet from $120.00 to $135.00 and gave the company an “equal weight” rating in a research report on Friday, January 6th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $128.86.

Zimmer Biomet Stock Down 0.4 %

Shares of NYSE:ZBH opened at $125.48 on Wednesday. The stock’s 50-day moving average price is $123.44 and its two-hundred day moving average price is $114.62. The company has a current ratio of 1.98, a quick ratio of 1.05 and a debt-to-equity ratio of 0.41. Zimmer Biomet Holdings, Inc. has a 12-month low of $100.39 and a 12-month high of $135.05. The firm has a market cap of $26.33 billion, a price-to-earnings ratio of 95.06, a PEG ratio of 2.37 and a beta of 1.04.

Zimmer Biomet (NYSE:ZBHGet Rating) last issued its quarterly earnings results on Wednesday, November 2nd. The medical equipment provider reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.56 by $0.02. Zimmer Biomet had a return on equity of 11.92% and a net margin of 3.89%. The firm had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.64 billion. During the same period last year, the company earned $1.81 EPS. The firm’s quarterly revenue was down 13.2% on a year-over-year basis. On average, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 6.84 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, January 31st. Stockholders of record on Tuesday, December 27th will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.77%. The ex-dividend date of this dividend is Friday, December 23rd. Zimmer Biomet’s dividend payout ratio is currently 72.73%.

Zimmer Biomet Profile

(Get Rating)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T.

Recommended Stories

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.